Calimmune Overview
Founded
2006
Status
Acquired/Merged
Employees
40
Latest Deal Type
M&A
Latest Deal Amount
$416M
Calimmune General Information
Description
Developer of a gene modification and cell delivery technology designed to translate the promise of gene therapy into effective and accessible products that have the power to restore health and improve lives. The company's gene modification and cell delivery technology works by genetically modifying patients' own cells to shield and strengthen their immune system and create enduring and life-long protection for individuals living with a broad range of debilitating and currently incurable diseases, enabling physicians to address the unique needs of individuals at different stages of HIV infection and with various treatment histories.
Contact Information
Website
Ownership Status
Acquired/Merged
(Operating Subsidiary)
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Office
- 5151 East Broadway Boulevard
- Suite 1020
- Tucson, AZ 85711
- United States
+1 (310) 000-0000
Calimmune Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Merger/Acquisition | 11-Sep-2017 | $416M | 000.00 | 00000 | Completed | Clinical Trials - Phase 2 |
| 6. Later Stage VC (Series C) | 000.00 | Completed | Clinical Trials - Phase 2 | |||
| 5. Later Stage VC (Series B) | 27-May-2015 | 000.00 | 000.00 | 00000 | Completed | Clinical Trials - Phase 2 |
| 4. Later Stage VC (Series A) | 01-Dec-2013 | 000 | 00.000 | 0000 | Completed | Clinical Trials - Phase 2 |
| 3. Early Stage VC | 16-Sep-2011 | 000 | 00.000 | Completed | Generating Revenue | |
| 2. Angel (individual) | 01-Jun-2010 | $50K | $50K | Completed | Startup | |
| 1. Grant | $8.28M | Completed | Startup |
Calimmune Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | 0,000,000 | 00.000000 | 00 | 000.0 | 000.0 | 00 | 000.0 | 0.000 |
| Series A | 0,000,000 | 00.000000 | 00 | 000.0 | 000.0 | 00 | 000 | 00.000 |
| Series 4 | 000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 0.000 |
| Series 3 | 00,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 0.000 |
| Series 2 | 107,000 | $0.001000 | 8% | $4.94 | $4.94 | 1x | $4.94 | 0.85% |
| Series 1 | 188,136 | $0.001000 | 8% | $5 | $5 | 1x | $5 | 1.49% |
Calimmune Competitors (51)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| ViaCyte | Venture Capital-Backed | San Diego, CA | 00 | 00000 | 00000000000 | 00000 |
| 00000000 000000000 | Formerly VC-backed | Bedford, MA | 000 | 00000 | 00000000 | 00000 |
| 000000 00000000000 | Corporation | Cambridge, MA | 000 | 00000 | 000000 - 000 | 00000 |
| 00000 000000000000 | Venture Capital-Backed | Stockholm, Sweden | 0 | 000.00 | 00000000000 | 000.00 |
| 000000 | Venture Capital-Backed | Lebanon, NH | 000 | 00000 | 0000000000 0 | 00000 |
Calimmune Executive Team (14)
3 Former Executives
Calimmune Board Members (8)
| Name | Representing | Role | Since |
|---|---|---|---|
| David Baltimore Ph.D | Self | Co-Founder & Co-Chairman | 000 0000 |
| Harry George III | Self | Board Member | 000 0000 |
| Jon Faiz Kayyem Ph.D | Calimmune | Board Member and Co-Founder | 000 0000 |
| Scott Greer | Self | Co-Chairman | 000 0000 |
4 Former Board Members
Calimmune Former Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| AbbVie Ventures | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
| Alexandria Venture Investments | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
| California Institute for Regenerative Medicine | Government | 000 0000 | 000000 0 | ||
| Cycad Group | Venture Capital | Minority | 000 0000 | 000000 0 | |
| DVI Equity Partners | Venture Capital | Minority | 000 0000 | 000000 0 |
Ready to get started?
Request a free trial